Current law prohibits Medicare from covering obesity drugs and gives states flexibility to cover weight loss drugs under Medicaid Limitations on coverage for obesity drugs in Medicare and Medicaid mean that millions of people who have obesity and might benefit from taking GLP-1s may be unable to access them unless they are able to pay the full cash price out of their own pockets, which would likely be prohibitive for people with Medicaid who must have low incomes to qualify for the program, as well as for many people on Medicare with low and modest incomes
In addition to expert medication management, our dedicated team offers comprehensive support, including nutrition counseling, behavior modification strategies, and regular follow-up appointments
The physiology of glucagon-like peptide-1
Triple G is the colloquial term used in research and medical media to describe Retatrutides three-receptor mechanism, GLP-1, GIP, and Glucagon
Researching an off-ramp Clinicians have a body of research on starting GLP-1s, but theres less evidence on how to stop them, Biermann says
The CNPV program may play an increasingly important role in speeding up access to therapies that address urgent health challenges